Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results
Chigusa Morizane, H. Ikeda(Tokyo National Hospital), Yoriko Takezako(Tokyo National Hospital), Takuji Okusaka(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Hideki Ueno(National Defense Medical College), Yuta Ito(Tokyo National Hospital), M. Ikeda, Yoshikazu Kagami(Tokyo National Hospital)
Cited by 0
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2011|713
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
|International Journal of Clinical Oncology|2015|600